Top executives from AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, GSK plc, Pfizer Inc., Novartis AG, and Takeda Pharmaceutical Co. Ltd. have again gathered under one roof for the annual China Development Forum held March 24-25 in Beijing.
Stay Or Exit? Global Health Players Ponder New China Trajectory
Localization Takes New Shape
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
More from China
More from Focus On Asia
• By
Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs
• By
Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.
• By
Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.